b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="vir" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2886951/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886951/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="The Journal of General Virology" /><meta name="citation_title" content="Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison" /><meta name="citation_authors" content="Edward Wright, Nigel J. Temperton, Denise A. Marston, Lorraine M. McElhinney, Anthony R. Fooks, Robin A. Weiss" /><meta name="citation_date" content="September 2008" /><meta name="citation_issue" content="Pt 9" /><meta name="citation_volume" content="89" /><meta name="citation_firstpage" content="2204" /><meta name="citation_doi" content="10.1099/vir.0.2008/000349-0" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2886951/?report=abstract" /><meta name="citation_pmid" content="18753230" /><meta name="DC.Title" content="Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Microbiology Society" /><meta name="DC.Contributor" content="Edward Wright" /><meta name="DC.Contributor" content="Nigel J. Temperton" /><meta name="DC.Contributor" content="Denise A. Marston" /><meta name="DC.Contributor" content="Lorraine M. McElhinney" /><meta name="DC.Contributor" content="Anthony R. Fooks" /><meta name="DC.Contributor" content="Robin A. Weiss" /><meta name="DC.Date" content="2008 Sep" /><meta name="DC.Identifier" content="10.1099/vir.0.2008/000349-0" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison" /><meta property="og:type" content="article" /><meta property="og:description" content="Cross-neutralization between rabies virus (RABV) and two European bat lyssaviruses (EBLV-1 and -2) was analysed using lentiviral pseudotypes as antigen vectors. Glycoprotein (G-protein) cDNA from RABV challenge ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886951/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-vir.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2886951/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2886951/pdf/2204.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B35F5E9A34A6100000000098F098D.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=%22J Gen Virol%22[journal]" class="navlink">J Gen Virol</a></li><li class="accid">PMC2886951</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-vir.jpg" alt="Logo of vir" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher\'s site" title="Link to Publisher\'s site" shape="default" coords="0,0,499,74" href="http://jgv.microbiologyresearch.org/content/journal/jgv" target="pmc_ext" ref="reftype=publisher&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">J Gen Virol</span>. 2008 Sep; 89(Pt 9): 2204\xe2\x80\x932213. </span></div><div>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1099%2Fvir.0.2008%2F000349-0" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1099/vir.0.2008/000349-0</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2886951</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/18753230">18753230</a></div></div></div></div><h1 class="content-title">Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Wright%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139956936728144" co-class="co-affbox">Edward Wright</a>,<sup>1</sup> <a href="/pubmed/?term=Temperton%20NJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139956933312624" co-class="co-affbox">Nigel J. Temperton</a>,<sup>1</sup> <a href="/pubmed/?term=Marston%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139956971634272" co-class="co-affbox">Denise A. Marston</a>,<sup>2</sup> <a href="/pubmed/?term=McElhinney%20LM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139957008382560" co-class="co-affbox">Lorraine M. McElhinney</a>,<sup>2</sup> <a href="/pubmed/?term=Fooks%20AR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139956935855584" co-class="co-affbox">Anthony R. Fooks</a>,<sup>2</sup> and  <a href="/pubmed/?term=Weiss%20RA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230" class="affpopup" co-rid="_co_idm139956925507136" co-class="co-affbox">Robin A. Weiss</a><sup>1</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139956936728144"><h3 class="no_margin">Edward Wright</h3><p><sup>1</sup>MRC&#x0002f;UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK</p><div>Find articles by <a href="/pubmed/?term=Wright%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Edward Wright</a></div></div><div id="_co_idm139956933312624"><h3 class="no_margin">Nigel J. Temperton</h3><p><sup>1</sup>MRC&#x0002f;UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK</p><div>Find articles by <a href="/pubmed/?term=Temperton%20NJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Nigel J. Temperton</a></div></div><div id="_co_idm139956971634272"><h3 class="no_margin">Denise A. Marston</h3><p><sup>2</sup>Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency &#x00028;Weybridge&#x00029;, WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK</p><div>Find articles by <a href="/pubmed/?term=Marston%20DA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Denise A. Marston</a></div></div><div id="_co_idm139957008382560"><h3 class="no_margin">Lorraine M. McElhinney</h3><p><sup>2</sup>Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency &#x00028;Weybridge&#x00029;, WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK</p><div>Find articles by <a href="/pubmed/?term=McElhinney%20LM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Lorraine M. McElhinney</a></div></div><div id="_co_idm139956935855584"><h3 class="no_margin">Anthony R. Fooks</h3><p><sup>2</sup>Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency &#x00028;Weybridge&#x00029;, WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK</p><div>Find articles by <a href="/pubmed/?term=Fooks%20AR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Anthony R. Fooks</a></div></div><div id="_co_idm139956925507136"><h3 class="no_margin">Robin A. Weiss</h3><p><sup>1</sup>MRC&#x0002f;UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK</p><div>Find articles by <a href="/pubmed/?term=Weiss%20RA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18753230">Robin A. Weiss</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139956932059280_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139956932059280_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139956932059280_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139956932059280_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1"><sup>1</sup>MRC&#x0002f;UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK</div><div class="fm-affl" lang="en" id="aff2"><sup>2</sup>Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency &#x00028;Weybridge&#x00029;, WHO Collaborating Centre for the Characterisation of Rabies and Rabies-related Viruses, New Haw, Addlestone KT15 3NB, UK</div><div id="idm139956925167328"><strong>Correspondence</strong>: Anthony R. Fooks: <a href="mailto:dev@null" data-email="ku.vog.isg.arfed.alv@skoof.t" class="oemail">ku.vog.isg.arfed.alv@skoof.t</a>: Robin A. Weiss: <a href="mailto:dev@null" data-email="ku.ca.lcu@ssiew.r" class="oemail">ku.ca.lcu@ssiew.r</a></div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139956932059280_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2008 Jan 14; Accepted 2008 Apr 11.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139956932059280_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2008, Crown Copyright</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2886951/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2>Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">\n               [Supplementary Material]\n            </div>\n            \n            <div><a href="/pmc/articles/PMC2886951/bin/supp_89_9_2204__index.html" data-ga-action="click_feat_suppl">supp_89_9_2204__index.html</a><span style="color:gray"> (1003 bytes)</span></div><div class="small guid">GUID:\xc2\xa05C896AB5-C5E4-46EB-8056-C65EA56EF1EC</div>\n            <div><a href="/pmc/articles/PMC2886951/bin/supp_89_9_2204__1.pdf" data-ga-action="click_feat_suppl">supp_89_9_2204__1.pdf</a><span style="color:gray"> (67K)</span></div><div class="small guid">GUID:\xc2\xa09B13B5BE-3EF1-4353-B53E-DD36E4CEBEA3</div>\n         </div></dd></dl></div><div id="idm139956937583344" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139956937583344title">Abstract</h2><!--article-meta--><div><p id="__p1" class="p p-first-last">Cross-neutralization between rabies virus &#x00028;RABV&#x00029; and two European bat lyssaviruses &#x00028;EBLV-1 and -2&#x00029; was analysed using lentiviral pseudotypes as antigen vectors. Glycoprotein &#x00028;G-protein&#x00029; cDNA from RABV challenge virus standard-11 &#x00028;CVS-11&#x00029; and EBLV-1 and -2 were cloned and co-expressed with human immunodeficiency virus &#x00028;HIV&#x00029; or murine leukemia virus &#x00028;MLV&#x00029; <em>gag</em>&#x02013;<em>pol</em> and packageable green fluorescent protein &#x00028;GFP&#x00029; or luciferase reporter genes in human cells. The harvested lentiviral &#x00028;HIV&#x00029; vector infected over 40&#x0200a;&#x00025; of baby hamster kidney &#x00028;BHK&#x00029; target cells, providing high-titre pseudotype stocks. Tests on blinded antibody-positive &#x00028;<em>n</em>&#x0003d;15&#x00029; and -negative &#x00028;<em>n</em>&#x0003d;45&#x00029; sera, predetermined by the fluorescent antibody virus neutralization &#x00028;FAVN&#x00029; test approved by the World Health Organization &#x00028;WHO&#x00029; and Office International des Epizooties &#x00028;OIE&#x00029;, revealed that the CVS-11 pseudotype assay had 100&#x0200a;&#x00025; concordance with FAVN and strongly correlated with neutralization titres &#x00028;<em>r</em><sup>2</sup>&#x0003d;0.89&#x00029;. Cross-neutralization tests using sera from RABV-vaccinated humans and animals on pseudotypes with CVS-11, EBLV-1 and EBLV-2 envelopes showed that the relative neutralization titres correlated broadly with the degree of G-protein diversity. Pseudotypes have three major advantages over live-virus neutralization tests: &#x00028;i&#x00029; they can be handled in low-biohazard-level laboratories; &#x00028;ii&#x00029; the use of reporter genes such as GFP or <em>&#x003b2;</em>-galactosidase will allow the assay to be undertaken at low cost in laboratories worldwide; &#x00028;iii&#x00029; each assay requires &#x0003c;10&#x02005;&#x003bc;l serum. This robust microassay will improve our understanding of the protective humoral immunity that current rabies vaccines confer against emerging lyssaviruses, and will be applicable to surveillance studies, thus helping to control the spread of rabies.</p></div></div><div id="__sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec1title">INTRODUCTION</h2><p id="__p2" class="p p-first">Rabies virus &#x00028;RABV&#x00029; has the highest human case fatality rate of any viral disease, nearly 100&#x0200a;&#x00025; in individuals who do not receive one of the available prophylaxes or post-exposure treatment. This high mortality rate coupled with the worldwide distribution of RABV means that approximately 55&#x0200a;000 people are killed each year, the main burden being borne by children in the developing world &#x00028;<a href="#r34" rid="r34" class=" bibr popnode">WHO, 2006</a>&#x00029;. There are effective pre- and post-exposure vaccines that are frontline mechanisms, along with the control of animal reservoirs, for combating the spread of the virus to susceptible animal hosts. These vaccines stimulate the production of virus-neutralizing antibodies &#x00028;VNAs&#x00029; to the envelope glycoprotein &#x00028;G-protein&#x00029;, similar to the immunity conferred by live virus infections, where neutralizing immune responses to RABV are directed against the viral G-protein &#x00028;<a href="#r9" rid="r9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512540">Cox <em>et al.</em>, 1977</a>&#x00029;. The host immune response also includes non-neutralizing antibodies and cell-mediated immunity to the nucleoprotein &#x00028;<a href="#r14" rid="r14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512569">Dietzschold <em>et al.</em>, 1987</a>&#x00029;. Increased monitoring of humoral responses to RABV vaccines and studies of the prevalence of natural RABV and lyssavirus infections in domestic and wild species would allow for a more specific and proportionate response in endemic countries. However, the majority of these countries have resource-limited laboratories and the routine method to test for RABV VNAs, in most countries, involves high containment, biosafety level 3 facilities. Thus, it is currently not practical to undertake thorough and sustained surveillance as the screening cannot be undertaken in the majority of these locations.</p><p id="__p3">European bat lyssavirus type-1 &#x00028;EBLV-1&#x00029; and European bat lyssavirus type-2 &#x00028;EBLV-2&#x00029; predominantly infect insectivorous bats. However, rare zoonotic events occur that have resulted in EBLV-1 infections of humans, sheep and a stone marten &#x00028;<a href="#r18" rid="r18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512533">Fooks <em>et al.</em>, 2003</a>&#x00029;. Previous work has shown that antibody responses in individuals vaccinated with the RABV human diploid cell vaccine &#x00028;HDCV&#x00029; are able to neutralize RABV &#x0005b;rabies virus &#x00028;RV61&#x00029; and challenge virus standard-11 &#x00028;CVS-11&#x00029;&#x0005d;, EBLV-1, EBLV-2 and Australian bat lyssavirus &#x00028;<a href="#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512552">Brookes <em>et al.</em>, 2005</a>; <a href="#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512564">Hanlon <em>et al.</em>, 2005</a>&#x00029;. However, the same vaccine does not confer complete protection against the emerging Eurasian lyssavirus strains Aravan virus, Khujand virus, Irkut virus and West Caucasian Bat virus &#x00028;<a href="#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512547">Hanlon <em>et al.</em>, 2005</a>&#x00029; or against lyssaviruses belonging to phylogroup II &#x00028;<a href="#r1" rid="r1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512562">Badrane <em>et al.</em>, 2001</a>; <a href="#r16" rid="r16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512555">Fooks, 2004</a>; <a href="#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512556">Hanlon <em>et al.</em>, 2005</a>&#x00029;.</p><p id="__p4">Pseudotypes are viruses that carry the genome and core of one virus and the envelope of another. There are many examples of pseudotypes being used for virus receptor identification and cell entry &#x00028;<a href="#r11" rid="r11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512536">Dalgleish <em>et al.</em>, 1984</a>; <a href="#r35" rid="r35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512565">Wool-Lewis &#x00026; Bates, 1998</a>&#x00029; and for virus neutralization by antibodies &#x00028;<a href="#r2" rid="r2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512544">Bartosch <em>et al.</em>, 2003</a>; <a href="#r5" rid="r5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512551">Clapham <em>et al.</em>, 1984</a>; <a href="#r30" rid="r30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_258120330">Temperton <em>et al.</em>, 2005</a>&#x00029;. Retroviral pseudotypes &#x0005b;based on the gammaretrovirus murine leukemia virus &#x00028;MLV&#x00029; or lentivirus human immunodeficiency virus &#x00028;HIV&#x00029;&#x0005d; that bear vesicular stomatitis virus &#x00028;VSV&#x00029; G-proteins are commonly used as vectors for gene therapy &#x00028;<a href="#r24" rid="r24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512542">Naldini <em>et al.</em>, 1996</a>; <a href="#r29" rid="r29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512563">Takeuchi <em>et al.</em>, 1996</a>; <a href="#r36" rid="r36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512560">Zufferey <em>et al.</em>, 1997</a>&#x00029;. In fact, retroviral pseudotypes using RABV envelopes have previously been shown to function as neurotropic gene vectors &#x00028;<a href="#r13" rid="r13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512530">Desmaris <em>et al.</em>, 2001</a>; <a href="#r22" rid="r22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512557">Mazarakis <em>et al.</em>, 2001</a>; <a href="#r23" rid="r23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512550">Mentis <em>et al.</em>, 2006</a>&#x00029;. We have previously shown with SARS-coronavirus spike S-protein and H5N1 influenza virus haemagglutinin that retroviral pseudotypes expressing these envelope proteins can be used in sensitive and specific assays for the detection of VNAs to these pathogens &#x00028;<a href="#r30" rid="r30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_258120331">Temperton <em>et al.</em>, 2005</a>, <a href="#r31" rid="r31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_565692654">2007</a>&#x00029;.</p><p id="__p5" class="p p-last">Here we report the analysis of neutralizing antibodies to CVS-11, EBLV-1 and EBLV-2 in sera from RABV-vaccinated humans, canines and felines, using lentiviral pseudotypes. As the only lyssavirus protein present in the pseudotypes is the G-protein, we can accurately determine the precise role that antibodies targeting this protein play in cross-neutralization. Virus-neutralizing titres are correlated against full-length G-protein sequences encoding the glycoprotein. This powerful, novel assay for the detection of RABV VNA using CVS-11 pseudotypes can be adapted to meet the needs of many laboratories worldwide without requiring high containment. Using pseudotypes with the luciferase reporter, we established the assay\'s sensitivity and specificity with serum samples that were previously characterized using the World Health Organization &#x00028;WHO&#x00029; and Office International des Epizooties &#x00028;OIE&#x00029; fluorescent antibody virus neutralization test &#x00028;FAVN&#x00029;.</p></div><div id="__sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec2title">METHODS</h2><div id="__sec3" class="sec sec-first"><h3 id="__sec3title">Cell lines.</h3><p id="__p6" class="p p-first-last">Human embryonic kidney 293T cells &#x00028;HEK-293T; originally referred to as 293&#x0002f;tsAJ609neo; <a href="#r15" rid="r15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512554">DuBridge <em>et al.</em>, 1987</a>&#x00029; were used for transfections and to determine the tropism range of the pseudotyped virus together with the NP2 human glioma cell line &#x00028;<a href="#r26" rid="r26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512538">Soda <em>et al.</em>, 1999</a>&#x00029;, baby hamster kidney 21 cells clone 13 &#x00028;BHK-21; originally obtained from the American Tissue Culture Collection as ATCC CCL-10; <a href="#r27" rid="r27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512535">Stoker &#x00026; Macpherson, 1964</a>&#x00029;, human rhabdomyosarcoma cells &#x00028;TE671; <a href="#r28" rid="r28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512528">Stratton <em>et al.</em>, 1989</a>&#x00029; and mouse neuroblastoma cells &#x00028;N2A; originally obtained from ATCC CCL-131&#x00029;. HEK-293T cells were maintained in Dulbecco\'s modified Eagle medium &#x00028;DMEM&#x00029; supplemented with Glutamax and 15&#x0200a;&#x00025; fetal calf serum &#x00028;FCS&#x00029; at 10&#x0200a;&#x00025; CO<sub>2</sub>; all other cell lines were cultured in DMEM with 10&#x0200a;&#x00025; FCS and 1&#x0200a;&#x00025; penicillin&#x0002f;streptomycin at 5&#x0200a;&#x00025; CO<sub>2</sub>.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Plasmids and pseudotype production.</h3><p id="__p7" class="p p-first-last">For transfection, 5&#x000d7;10<sup>6</sup> HEK-293T cells were plated 24&#x02005;h prior to addition of a complex comprising plasmid DNA and Fugene 6 that facilitated DNA transport into the cells &#x00028;as described by the manufacturer; Roche&#x00029;. The HIV type 1 &#x00028;HIV-1&#x00029; <em>gag</em>-<em>pol</em> construct pCMV-&#x00394;8.91 &#x00028;<a href="#r36" rid="r36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512567">Zufferey <em>et al.</em>, 1997</a>&#x00029; and green fluorescent protein &#x00028;GFP&#x00029; reporter construct pCSGW &#x00028;pHR&#x02032;SIN-cPPT-SGW, which incorporates the eGFP cassette driven by the U3 part of the spleen focus forming virus long-terminal repeat sequence; <a href="#r12" rid="r12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512559">Demaison <em>et al.</em>, 2002</a>&#x00029; or the firefly luciferase reporter construct pCSFLW &#x00028;where the luciferase gene has been cloned into pCSGW in place of GFP; a kind gift from Dr B. Capecchi, Novartis Vaccines and Diagnostics, Siena, Italy&#x00029;, were transfected concurrently with the required envelope construct at a ratio of 1&#x0200a;:&#x0200a;1.5&#x0200a;:&#x0200a;1&#x02005;&#x003bc;g, respectively. MLV <em>gag</em>-<em>pol</em> construct pCMVi &#x00028;<a href="#r33" rid="r33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512543">Towers <em>et al.</em>, 2000</a>&#x00029; and GFP reporter construct pCNCG &#x0005b;a LNCX plasmid &#x00028;CLONTECH&#x00029; encoding enhanced GFP, with CMV driving expression of the RNA&#x0005d; or firefly luciferase reporter construct &#x00028;<a href="#r25" rid="r25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512568">Op De Beeck <em>et al.</em>, 2004</a>&#x00029; were used at the same ratio as the HIV constructs. In each case, cells were washed 24&#x02005;h post-transfection and incubated with fresh media. Supernatants were harvested 48 and 72&#x02005;h post-transfection and titrated on HEK-293T, NP2, BHK-21, TE671 and N2A cell lines. The remaining virus was stored at &#x02212;80&#x02005;&#x000b0;C. Fresh or frozen pseudotype aliquots were used for virus titrations and neutralization assays, respectively. Each round of freeze-thaw resulted in an average loss in virus titre of 5.7&#x0200a;&#x00025; for CVS-11, 3&#x0200a;&#x00025; for EBLV-1, 5.3&#x0200a;&#x00025; for EBLV-2 and 2&#x00025; for VSV pseudotype &#x00028;see Supplementary Fig. S1, available with the online version of this paper&#x00029;.</p></div><div id="__sec5" class="sec"><h3 id="__sec5title">Viruses and envelope cloning.</h3><p id="__p8" class="p p-first">The RABV isolate used in this study was CVS-11 &#x00028;ATCC VR-959&#x00029;. Its G-gene sequence was amplified using the RT-PCR Titan kit as described by the manufacturer &#x00028;Roche&#x00029;, with primers that were designed based on the published sequence &#x00028;GenBank accession number <a id="__tag_394678657" class="tag_hotlink" href="/nuccore/EU352767" ref="/nuccore/EU352767"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"EU352767","term_id":"169409606","term_text":"EU352767"}}</span>EU352767</a>&#x00029;. EBLV-1 &#x00028;isolate RV 9&#x00029; and EBLV-2 &#x00028;isolate RV 1787&#x00029; G-gene sequences &#x00028;GenBank accession numbers <a id="__tag_394678655" class="tag_hotlink" href="/nuccore/EU352768" ref="/nuccore/EU352768"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"EU352768","term_id":"169409608","term_text":"EU352768"}}</span>EU352768</a> and <a id="__tag_394678656" class="tag_hotlink" href="/nuccore/EU352769" ref="/nuccore/EU352769"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"EU352769","term_id":"169409610","term_text":"EU352769"}}</span>EU352769</a>, respectively&#x00029; were subcloned from existing transfer plasmids using specific PCR primer sets. Primers are listed in Supplementary Table S1. The PCRs introduced unique <em>Kpn</em>I and <em>Xho</em>I restriction sites at the 5&#x02032; and 3&#x02032; ends of the genes. Once amplified, they were ligated into pI.18, a pUC-based plasmid incorporating the human cytomegalovirus immediate early promoter &#x00028;<a href="#r10" rid="r10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512537">Cox <em>et al.</em>, 2002</a>&#x00029;, and sequenced to ensure correct alignment.</p><p id="__p9" class="p p-last">The VSV G-protein &#x00028;Indiana serotype&#x00029; expression vector pMD.G has been described previously &#x00028;<a href="#r24" rid="r24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512566">Naldini <em>et al.</em>, 1996</a>&#x00029; and was used to create a control pseudotype virus.</p></div><div id="__sec6" class="sec"><h3 id="__sec6title">Western blot.</h3><p id="__p10" class="p p-first-last">CVS-11, &#x00394;Env &#x00028;where only the plasmids containing <em>gag</em>-<em>pol</em> and reporter gene were transfected into cells&#x00029;, HIV and VSV pseudotyped viral particles were purified on a 25&#x0002f;40&#x0200a;&#x00025; sucrose cushion to remove any G-protein not incorporated into the viral envelope before being separated by SDS-PAGE. Cell extracts for Western blots were prepared by resuspending 1&#x000d7;10<sup>6</sup> HEK-293T cells &#x00028;72&#x02005;h post-transfection&#x00029; in SDS-PAGE loading buffer &#x00028;100&#x02005;mM Tris&#x0002f;HCl, pH&#x02005;6.8; 20&#x0200a;&#x00025;, v&#x0002f;v, glycerol; 143&#x02005;mM 2-mercaptoethanol; 10&#x0200a;&#x00025;, v&#x0002f;v, SDS; and 0.025&#x0200a;&#x00025;, w&#x0002f;v, bromophenol blue&#x00029;. Proteins were transferred, using semi-dry equipment, to a PVDF transfer membrane &#x00028;Hybond-P; Amersham Biosciences&#x00029; and blotted with SNB1, a primary mouse anti-RABV G-protein monoclonal antibody &#x00028;1&#x0200a;:&#x0200a;500; a kind gift from Merial&#x00029;. Immunoblots for VSV G-protein were performed using an anti-VSV G-protein monoclonal antibody &#x00028;clone P5D4; 1&#x0200a;:&#x0200a;10&#x0200a;000; Sigma&#x00029;. To determine protein loading&#x0002f;transfer, an identically loaded gel was stained with Coomassie blue and the nitrocellulose membrane was blotted with two anti-HIV-1 Gag p53&#x0002f;p24 antibodies &#x00028;EVA365 and EVA366 diluted 1&#x0200a;:&#x0200a;100; AIDS Reagents, NIBSC&#x00029; or an anti-actin antibody able to detect all isoforms &#x00028;diluted 1&#x0200a;:&#x0200a;750; Sigma&#x00029;. For all blots, an anti-mouse horseradish peroxidase-conjugated IgG secondary antibody &#x00028;diluted 1&#x0200a;:&#x0200a;5000; Amersham Biosciences&#x00029; was then used prior to antibody binding detection by enhanced chemiluminescence &#x00028;Amersham Biosciences&#x00029;.</p></div><div id="__sec7" class="sec"><h3 id="__sec7title">Serum samples.</h3><p id="__p11" class="p p-first-last">Varied samples comprising sera from RABV-vaccinated humans, dogs and cats and the OIE standard reference dog serum diluted to 0.5&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup> with Stabilzyme &#x00028;Surmodics Inc.&#x00029; were tested. Detailed descriptions of each serum are given in Supplementary Table S2. To determine the stringency of the assay, a total of 60 serum samples were used; these were 48 dog &#x00028;40&#x0002f;8, negative&#x0002f;positive; as initially determined by FAVN&#x00029;, nine cat &#x00028;5&#x0002f;4&#x00029; and three human &#x00028;0&#x0002f;3&#x00029; sera. An additional rabbit serum, raised against EBLV-2, was used for the cross-neutralization experiments. Sera were titrated using twofold serial dilutions to obtain the IC<sub>100</sub>. All experiments were undertaken at least in duplicate; if the titre varied by more than one doubling dilution it was repeated a third time and the geometric mean was recorded, in keeping with standard serological practice &#x00028;<a href="#r3" rid="r3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512545">Bresson <em>et al.</em>, 2006</a>&#x00029;.</p></div><div id="__sec8" class="sec sec-last"><h3 id="__sec8title">Neutralization assays.</h3><p id="__p12" class="p p-first">Live virus experiments were undertaken using the FAVN as described previously using CVS-11 &#x00028;<a href="#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512532">Brookes <em>et al.</em>, 2005</a>; <a href="#r6" rid="r6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512541">Cliquet <em>et al.</em>, 1998</a>&#x00029;. Pseudotype TCID<sub>50</sub> values were calculated using the end point method &#x00028;<a href="#r8" rid="r8" class=" bibr popnode">Condit, 2001</a>&#x00029;; the CVS-11 pseudotype was serially diluted in multiple replicates which resulted in infection of all replicates at low dilutions, no infection at high dilutions and infection in some but not all inoculations at intermediate dilutions. The dilution of virus that resulted in infection of 50&#x0200a;&#x00025; of replicates could then be calculated.</p><p id="__p13">In a 96-well plate, 90&#x000d7;TCID<sub>50</sub> CVS-11 pseudotyped virus that resulted in an output of 8&#x000d7;10<sup>5</sup> relative light units &#x00028;RLU&#x00029; was incubated with doubling dilutions of sera for 1&#x02005;h at 37&#x0200a;&#x00025; &#x00028;5&#x0200a;&#x00025; CO<sub>2</sub>&#x00029; before the addition of 1&#x000d7;10<sup>4</sup> BHK-21 cells. These were incubated for a further 48&#x02005;h, after which 125&#x02005;&#x003bc;l medium was removed and 75&#x02005;&#x003bc;l Bright-Glo reagent &#x00028;Promega&#x00029; was added. Luciferase activity was detected 2.5&#x02005;min later by reading the plates on a Glomax 96 microplate luminometer &#x00028;Promega&#x00029;. End-point titres &#x00028;which are equivalent to IC<sub>100</sub> values&#x00029; were chosen, as used in FAVN tests. Our initial experiments using GFP reporter proteins were analysed by fluorescence microscopy and by flow cytometry &#x00028;FACScan; BD&#x00029;. For all results, background RLU &#x00028;virus alone or &#x00394;Env&#x00029; or GFP &#x00028;cells alone&#x00029; was deducted before analysis.</p><p id="__p14" class="p p-last">Cross-neutralization experiments were performed as above with the following mean pseudotype input &#x00028;RLU&#x00029;: CVS-11, 5.4&#x000d7;10<sup>5</sup>; EBLV-1, 4.5&#x000d7;10<sup>5</sup>; EBLV-2, 4.2&#x000d7;10<sup>5</sup>.</p></div></div><div id="__sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec9title">RESULTS</h2><div id="__sec10" class="sec sec-first"><h3 id="__sec10title">Expression of RABV G-protein and production of pseudotype particles</h3><p id="__p15" class="p p-first">To determine whether the viral G-proteins were being expressed on the envelope of the pseudotype virus, we performed a Western blot using supernatant from transfected cells and a RABV monoclonal antibody &#x00028;SNB1&#x00029;. The viral particles were purified from cell supernatant using a sucrose cushion to ensure that no secreted envelope was present in the samples. We were able to detect RABV envelope protein in the CVS-11 sample only &#x00028;lane 1; Fig.&#x02005;1a<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;. No RABV G-protein was detected in the three negative control lanes &#x00028;2&#x02013;4&#x00029; representing &#x00394;Env, HIV and VSV. To compare the level of CVS-11 G-protein expression on pseudotype particles with that of other viral envelopes, we blotted for VSV G-protein associated with a VSV pseudotype particle and observed similar levels of expression to CVS-11 &#x00028;Fig.&#x02005;1b<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;. Subsequent blotting of the membrane with anti-HIV-1 Gag p53&#x0002f;p24 antibodies confirmed the presence of lentiviral particles &#x00028;Fig.&#x02005;1c<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;. Protein loading was established by running an identical SDS gel and staining it with Coomassie blue &#x00028;Fig.&#x02005;1d<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;. We observed high, and comparable, expression of CVS-11 &#x00028;Fig.&#x02005;1e<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;, VSV G-protein &#x00028;Fig.&#x02005;1f<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029; and HIV-1 p53 &#x00028;Fig.&#x02005;1g<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029; when extracts from cells used to produce CVS-11 or VSV pseudotypes were analysed. An actin control was used to ensure equal protein loading &#x00028;Fig.&#x02005;1h<a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" class="fig-table-link figpopup" rid-figpopup="f1" rid-ob="ob-f1" co-legend-rid="lgnd_f1"><span></span></a>&#x00029;.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="f1" co-legend-rid="lgnd_f1"><a href="/pmc/articles/PMC2886951/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956939157328" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 2204fig1.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 2204fig1.jpg" src="/pmc/articles/PMC2886951/bin/2204fig1.jpg" /></div><div id="largeobj_idm139956939157328" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/figure/f1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_f1"><div><a class="figpopup" href="/pmc/articles/PMC2886951/figure/f1/" target="figure" rid-figpopup="f1" rid-ob="ob-f1">Fig. 1.</a></div><!--caption a7--><div class="caption"><p id="__p34">Expression of RABV-G, VSV-G and HIV-1 capsid proteins in pseudotypes and producer 293T cells. &#x00028;a&#x00029; An anti-RABV G-protein antibody was used in a Western blot of purified pseudotype samples with envelope glycolproteins of CVS-11 &#x00028;lane 1&#x00029;, &#x00394;Env &#x00028;lane 2&#x00029;, HIV &#x00028;lane 3&#x00029; and VSV &#x00028;lane 4&#x00029;. &#x00028;b&#x00029; A comparative immunoblot for VSV was undertaken using an anti-VSV G-protein antibody. &#x00028;c&#x00029; Protein transfer was measured by blotting the membrane with antibodies to p53 and p24 of HIV-1. &#x00028;d&#x00029; An identical SDS gel was stained with Coomassie blue to determine total protein loading. Cells used to produce CVS-11 &#x00028;lane 5&#x00029; and VSV &#x00028;lane 6&#x00029; pseudotypes were harvested 72&#x02005;h post-transfection and lysed in SDS-PAGE loading buffer. Extract equating to 4&#x000d7;10<sup>4</sup> cells was separated by SDS-PAGE and the levels of CVS-11 G-protein &#x00028;e&#x00029;, VSV G-protein &#x00028;f&#x00029;, HIV-1 p53&#x0002f;24 &#x00028;g&#x00029; and actin &#x00028;h&#x00029; were determined using monoclonal antibodies. &#x0002a;, p53 and p24 staining.</p></div></div></div><p id="__p16" class="p p-last">CVS-11 pseudotype virus preparations were made by packaging either GFP or firefly luciferase as a reporter gene and marker of infection. These were titrated on cell lines known to be permissive for infection with wild-type RABV, i.e. BHK and N2A cells, and others that had previously not been tested: 293T, TE671 and NP2. Luciferase-pseudotyped virus with an HIV &#x00028;lentiviral&#x00029; core produced up to 2.5 log<sub>10</sub> higher viral titres &#x00028;Fig.&#x02005;2a<a href="/pmc/articles/PMC2886951/figure/f2/" target="figure" class="fig-table-link figpopup" rid-figpopup="f2" rid-ob="ob-f2" co-legend-rid="lgnd_f2"><span></span></a>&#x00029; than an MLV &#x00028;gammaretroviral&#x00029; core &#x00028;Fig.&#x02005;2b<a href="/pmc/articles/PMC2886951/figure/f2/" target="figure" class="fig-table-link figpopup" rid-figpopup="f2" rid-ob="ob-f2" co-legend-rid="lgnd_f2"><span></span></a>&#x00029;. Conversely, GFP-MLV virus &#x00028;Fig.&#x02005;2b<a href="/pmc/articles/PMC2886951/figure/f2/" target="figure" class="fig-table-link figpopup" rid-figpopup="f2" rid-ob="ob-f2" co-legend-rid="lgnd_f2"><span></span></a>&#x00029; was more potent than GFP-HIV &#x00028;Fig.&#x02005;2a<a href="/pmc/articles/PMC2886951/figure/f2/" target="figure" class="fig-table-link figpopup" rid-figpopup="f2" rid-ob="ob-f2" co-legend-rid="lgnd_f2"><span></span></a>&#x00029;, except on BHK cells. The 293T and TE671 cell lines were highly permissive for both the GFP and luciferase CVS-11 pseudotypes, but BHKs gave the strongest results for HIV-based pseudotypes, and the highest luciferase titre overall. NP2 cells appeared to be almost entirely refractory to infection, while N2As were only permissive for MLV-based pseudotypes. All the results for luciferase and GFP virus across the different cell lines correlated, with the exception of the MLV virus stocks on BHK cells. These results indicate that the HIV vector titrated on BHK cells yielded the most sensitive system for CVS-11 pseudotypes. We recorded an approximate GFP pseudotype titre of 1.3&#x000d7;10<sup>5</sup>&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup> for CVS-11 pseudotypes and 6.5&#x000d7;10<sup>6</sup>&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup> for pseudotype virus with the VSV G-protein. Since BHK cells are also used for FAVN assays, it allowed a direct comparison of neutralization as described below.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="f2" co-legend-rid="lgnd_f2"><a href="/pmc/articles/PMC2886951/figure/f2/" target="figure" rid-figpopup="f2" rid-ob="ob-f2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956928869360" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2886951_2204fig2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 2204fig2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2886951/bin/2204fig2.jpg" /></a></div><div id="largeobj_idm139956928869360" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/figure/f2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_f2"><div><a class="figpopup" href="/pmc/articles/PMC2886951/figure/f2/" target="figure" rid-figpopup="f2" rid-ob="ob-f2">Fig. 2.</a></div><!--caption a7--><div class="caption"><p id="__p35">Cells permissive for the CVS-11 pseudotype virus. Aliquots of virus &#x00028;50&#x02005;&#x003bc;l&#x00029; with a lentiviral &#x00028;HIV; a&#x00029; or a retroviral &#x00028;MLV; b&#x00029; core were incubated with different cell lines to determine the most appropriate cell type to use in further assays. GFP results are shown as fluorescence micrographs and mean proportions of infected cells &#x00028;determined by flow cytometry&#x00029;. Viral titres for luciferase pseudotypes are given in RLU &#x00028;mean&#x000b1;<span class="small-caps">sd</span>&#x00029; and titres reported are after deduction of the background luciferase activity of &#x00394;Env pseudotypes observed on each cell line.</p></div></div></div></div><div id="__sec11" class="sec"><h3 id="__sec11title">Sensitivity of the neutralization assay using a CVS-11 pseudotype</h3><p id="__p17" class="p p-first">In order to determine whether incubating varying amounts of pseudotype with antibody affected IC<sub>100</sub> titres, increasing logs of pseudotypes were used in neutralization assays with the OIE reference standard, plus medium-titre &#x00028;RC-199&#x00029; and high-titre &#x00028;RC-195&#x00029; sera. Virus concentration was determined by TCID<sub>50</sub> and by luciferase RLU. Using an input of 1000&#x000d7;TCID<sub>50</sub> &#x00028;1&#x000d7;10<sup>7</sup> RLU&#x00029;, the OIE standard positive control &#x00028;0.5&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup>&#x00029; could not achieve complete neutralization &#x00028;Table&#x02005;1<a href="/pmc/articles/PMC2886951/table/t1/" target="table" class="fig-table-link figpopup" rid-figpopup="t1" rid-ob="ob-t1" co-legend-rid=""><span></span></a>&#x00029;. However, when the input was decreased to 100&#x000d7;TCID<sub>50</sub> &#x00028;1&#x000d7;10<sup>6</sup> RLU&#x00029; and then 10&#x000d7;TCID<sub>50</sub> &#x00028;1&#x000d7;10<sup>5</sup> RLU&#x00029;, the OIE standard was able to neutralize 100&#x0200a;&#x00025; at greater dilutions. The same effect was observed using sera from a feline &#x00028;RC-195&#x00029; and another canine &#x00028;RC-199&#x00029; sample. Thus, as the level of virus&#x0002f;antigen input increased, there was a concomitant decrease in the VNA titre &#x00028;Table&#x02005;1<a href="/pmc/articles/PMC2886951/table/t1/" target="table" class="fig-table-link figpopup" rid-figpopup="t1" rid-ob="ob-t1" co-legend-rid=""><span></span></a>&#x00029;.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="t1"><h3>Table 1.</h3><!--caption a7--><div class="caption"><p id="__p38">Effect of varying levels of pseudotype input on neutralization titres</p><p id="__p39">Sera were classified as low, medium or high by their FAVN titre</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956932887328" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" align="left" valign="bottom" colspan="1"><strong>Sera</strong></th><th colspan="3" align="center" valign="top" rowspan="1"><strong>Pseudotype virus input &#x00028;RLU&#x0002f;TCID<sub>50</sub>&#x00029;</strong></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1"><strong>1&#x000d7;10<sup>5</sup>&#x0002f;10</strong></th><th align="center" valign="top" rowspan="1" colspan="1"><strong>1&#x000d7;10<sup>6</sup>&#x0002f;100</strong></th><th align="center" valign="top" rowspan="1" colspan="1"><strong>1&#x000d7;10<sup>7</sup>&#x0002f;1000</strong></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Low &#x00028;0.5&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup>; OIE standard&#x00029;</td><td align="center" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medium &#x00028;23.4&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup>; RC-199&#x00029;</td><td align="center" valign="top" rowspan="1" colspan="1">2&#x0200a;560</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x0200a;280</td><td align="center" valign="top" rowspan="1" colspan="1">320</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High &#x00028;364.5&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup>; RC-195&#x00029;</td><td align="center" valign="top" rowspan="1" colspan="1">20&#x0200a;480</td><td align="center" valign="top" rowspan="1" colspan="1">10&#x0200a;240</td><td align="center" valign="top" rowspan="1" colspan="1">320</td></tr></tbody></table></div><div id="largeobj_idm139956932887328" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/table/t1/?report=objectonly">Open in a separate window</a></div></div><p id="__p18">Having established the working concentration of the luciferase pseudotype virus, we tested 50 blinded sera from RABV vaccine recipients to an end point of four doubling dilutions initially, to determine which samples were the negatives or failures &#x00028;&#x0003c;0.5&#x02005;IU&#x02005;ml<sup>&#x02212;1</sup>; Fig.&#x02005;3a<a href="/pmc/articles/PMC2886951/figure/f3/" target="figure" class="fig-table-link figpopup" rid-figpopup="f3" rid-ob="ob-f3" co-legend-rid="lgnd_f3"><span></span></a>&#x00029;. There were 44 of these, with poor or no response that gave insufficient protection according to OIE&#x0002f;WHO criteria, and six clearly positive sera with differing titres. The six positive sera were tested at a higher serum dilution in tandem with a further nine positive samples, blinded with respect to their FAVN neutralization titres &#x00028;Fig.&#x02005;3b<a href="/pmc/articles/PMC2886951/figure/f3/" target="figure" class="fig-table-link figpopup" rid-figpopup="f3" rid-ob="ob-f3" co-legend-rid="lgnd_f3"><span></span></a>&#x00029;. When unblinded, these results mirrored those obtained using the FAVN test. A panel of low-, medium- and high-titre RABV-specific sera failed to neutralize pseudotypes bearing the VSV G-protein &#x00028;data not shown&#x00029;.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="f3" co-legend-rid="lgnd_f3"><a href="/pmc/articles/PMC2886951/figure/f3/" target="figure" rid-figpopup="f3" rid-ob="ob-f3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956937363504" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2886951_2204fig3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 2204fig3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2886951/bin/2204fig3.jpg" /></a></div><div id="largeobj_idm139956937363504" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/figure/f3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_f3"><div><a class="figpopup" href="/pmc/articles/PMC2886951/figure/f3/" target="figure" rid-figpopup="f3" rid-ob="ob-f3">Fig. 3.</a></div><!--caption a7--><div class="caption"><p id="__p36">Comparison of neutralizing titres using FAVN and RABV lentiviral pseudotype reveals high specificity and sensitivity. &#x00028;a&#x00029; To determine the specificity of the assay, 50 blinded serum samples were tested. All 44 negative and six positive samples &#x00028;by FAVN&#x00029; were identified correctly. &#x00028;b&#x00029; Fifteen positive samples were subsequently tested to determine the sensitivity of the neutralization assay using lentiviral pseudotypes. &#x00028;c&#x00029; The results obtained for each sample tested were plotted on a scatter plot showing the correlation between FAVN and pseudotype results given in IU&#x02005;ml<sup>&#x02212;1</sup> and dilution respectively. The position of negative sera is shown in light print; two positive samples have the same IU and dilution values, so appear as one point.</p></div></div></div><p id="__p19" class="p p-last">To determine how sensitive the pseudotype assay was at differentiating between serum samples with different neutralizing titres, we compared the titres obtained using the pseudotype assay with FAVN titres. The two sets of titres correlated strongly, with those sera that had a high IU&#x02005;ml<sup>&#x02212;1</sup> reading also scoring a higher dilution result &#x00028;Table&#x02005;2<a href="/pmc/articles/PMC2886951/table/t2/" target="table" class="fig-table-link figpopup" rid-figpopup="t2" rid-ob="ob-t2" co-legend-rid=""><span></span></a>&#x00029;. These data also showed that different animal species &#x00028;feline, canine, human&#x00029; elicited a range of strong and weak VNA responses to RABV. Taken together and presented as a scatter plot, the results obtained revealed a high correlation coefficient &#x00028;<em>r</em><sup>2</sup>&#x0003d;0.89&#x00029; between pseudotype and FAVN titres &#x00028;Fig.&#x02005;3c<a href="/pmc/articles/PMC2886951/figure/f3/" target="figure" class="fig-table-link figpopup" rid-figpopup="f3" rid-ob="ob-f3" co-legend-rid="lgnd_f3"><span></span></a>&#x00029;.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="t2"><h3>Table 2.</h3><!--caption a7--><div class="caption"><p id="__p40">FAVN and pseudotype neutralizing titres for all serum samples</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956918804992" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2886951_2204tbl1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 2204tbl1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2886951/bin/2204tbl1.jpg" /></a></div><div id="largeobj_idm139956918804992" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/table/t2/?report=objectonly">Open in a separate window</a></div></div></div><div id="__sec12" class="sec sec-last"><h3 id="__sec12title">Cross-neutralization of CVS-11 and European bat lyssaviruses</h3><p id="__p20" class="p p-first">Having established a working protocol for the accurate determination of CVS-11 virus-neutralizing antibodies, we adapted the assay to detect humoral responses to pseudotypes bearing G-proteins from representative isolates of EBLV-1 and EBLV-2. We could then study what effect antibodies that specifically target the G-protein alone have on cross-neutralization, and whether any animal species elicit a more potent response than others.</p><p id="__p21">The titre of pseudotype virus obtained with EBLV-1 and EBLV-2 G-protein pseudotypes was comparable to that for CVS-11 and within a log<sub>10</sub> of the titre achieved with VSV G-protein &#x00028;Fig.&#x02005;4a<a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" class="fig-table-link figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span></span></a>&#x00029;.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="f4" co-legend-rid="lgnd_f4"><a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" rid-figpopup="f4" rid-ob="ob-f4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956936303776" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2886951_2204fig4.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 2204fig4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2886951/bin/2204fig4.jpg" /></a></div><div id="largeobj_idm139956936303776" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/figure/f4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_f4"><div><a class="figpopup" href="/pmc/articles/PMC2886951/figure/f4/" target="figure" rid-figpopup="f4" rid-ob="ob-f4">Fig. 4.</a></div><!--caption a7--><div class="caption"><p id="__p37">Cross-neutralization of RABV and bat lyssaviruses by rabbit, human, canine and feline sera. &#x00028;a&#x00029; EBLV-1 and EBLV-2 pseudotypes with GFP and luciferase reporters &#x00028;50&#x02005;&#x003bc;l&#x00029; were tested on BHK cells alongside CVS-11, &#x00394;Env and VSV controls. &#x00028;b&#x00029; IC<sub>100</sub> VNA titres for rabbit, human, canine and feline sera are reported for CVS-11, EBLV-1 and EBLV-2 luciferase pseudotypes and scatter plots with correlation co-efficients comparing CVS-11 and EBLV-1 &#x00028;c&#x00029;, CVS-11 and EBLV-2 &#x00028;d&#x00029; and EBLV-1 and EBLV-2 &#x00028;e&#x00029; are given. The position of negative sera is shown in light print &#x00028;c, e&#x00029;; two positive samples in &#x00028;c&#x00029; and &#x00028;d&#x00029; had the same serum dilution value for both viruses, so they appear as one point. For &#x00028;c&#x00029;, &#x00028;d&#x00029; and &#x00028;e&#x00029;, <em>n</em>&#x0003d;9.</p></div></div></div><p id="__p22" class="p p-last">We therefore compared the patterns observed for VNA responses of RABV antisera from different animals with different lyssaviruses &#x00028;Fig.&#x02005;4b<a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" class="fig-table-link figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span></span></a>&#x00029;. Human serum samples neutralized CVS-11 to the greatest degree, followed by EBLV-2 and then EBLV-1; the same neutralizing profile was observed in cats. The sera from dogs neutralized all three genotypes, but no obvious pattern was common to these samples. Antibodies in the rabbit serum also neutralized all three pseudotypes, with the greatest neutralization observed with EBLV-2. When all nine neutralizing responses against CVS-11 and EBLV-1 were compared &#x00028;Fig.&#x02005;4c<a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" class="fig-table-link figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span></span></a>&#x00029;, there was a correlation coefficient of 0.79, while that between CVS-11 and EBLV-2 was 0.90 &#x00028;Fig.&#x02005;4d<a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" class="fig-table-link figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span></span></a>&#x00029; and between EBLV-1 and EBLV-2 was 0.68 &#x00028;Fig.&#x02005;4e<a href="/pmc/articles/PMC2886951/figure/f4/" target="figure" class="fig-table-link figpopup" rid-figpopup="f4" rid-ob="ob-f4" co-legend-rid="lgnd_f4"><span></span></a>&#x00029;. Analysis of the full-length G-protein amino acid sequences used here revealed that they have a similar degree of divergence from each other, with EBLV-1 and EBLV-2 &#x00028;80&#x0200a;&#x00025;&#x00029; being marginally more closely related to each other than to CVS-11 &#x00028;70.1 and 73.7&#x0200a;&#x00025; respectively; Table&#x02005;3<a href="/pmc/articles/PMC2886951/table/t3/" target="table" class="fig-table-link figpopup" rid-figpopup="t3" rid-ob="ob-t3" co-legend-rid=""><span></span></a>&#x00029;. The <em>r</em><sup>2</sup> values for CVS-11 versus EBLV-1 and CVS-11 versus EBLV-2 rank in inverse order to the degree of amino acid diversity of their respective G-proteins.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="t3"><h3>Table 3.</h3><!--caption a7--><div class="caption"><p id="__p41">G-protein nucleotide and amino acid sequence identities for CVS-11, EBLV-1 and EBLV-2</p><p id="__p42">Values above the diagonal refer to nucleotide identities; values below the diagonal refer to amino acid identities</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139956925510176" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><strong>Virus</strong></th><th align="center" valign="top" rowspan="1" colspan="1"><strong>CVS-11</strong></th><th align="center" valign="top" rowspan="1" colspan="1"><strong>EBLV-1</strong></th><th align="center" valign="top" rowspan="1" colspan="1"><strong>EBLV-2</strong></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>CVS-11</strong></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">66.3</td><td align="center" valign="top" rowspan="1" colspan="1">69.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>EBLV-1</strong></td><td align="center" valign="top" rowspan="1" colspan="1">70.1</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">73.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><strong>EBLV-2</strong></td><td align="center" valign="top" rowspan="1" colspan="1">73.7</td><td align="center" valign="top" rowspan="1" colspan="1">80.0</td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm139956925510176" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2886951/table/t3/?report=objectonly">Open in a separate window</a></div></div></div></div><div id="__sec13" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec13title">DISCUSSION</h2><p id="__p23" class="p p-first">Our pseudotype particles that express RABV envelope&#x0002f;G-proteins are antigenically similar to those native proteins on wild-type, live RABV virus particles, which function to allow particle entry and are neutralized by anti-RABV sera. Using an antibody shown previously to detect RABV G-protein, we were able to detect these proteins in immunoblots conducted with our CVS-11 pseudotype virus. This antibody does not detect G-protein in &#x00394;Env virus &#x00028;lacking a RABV envelope glycoprotein&#x00029; or on pseudotypes bearing either the HIV envelope or VSV G-protein, although VSV and RABV are members of the same virus family, <em>Rhabdoviridae</em>. However, using a VSV-G monoclonal antibody, we observed the same, if not marginally less, incorporation of the envelope protein into the pseudotype. The levels of CVS-11 and VSV G-protein expression are also comparable in the transfected 293T producer cells, suggesting that the G-proteins incorporate with equal efficiency into the pseudotypes. As expected, the cleaved Gag p24 protein predominates in the mature pseudotype particle and the unspliced Gag p53 predominates in the 293T cells.</p><p id="__p24">The use of replication-competent isolates of highly pathogenic viruses is strictly regulated and, in the majority of countries, requires the use of category 3 or 4 containment laboratories. Using pseudotype technology, we have constructed modified lentiviral vectors and established an assay that utilizes these replication-incompetent particles to measure RABV VNA titres accurately. This method has the benefit of allowing experiments to be undertaken in category 2 biosafety laboratories, since the pseudotype is unable to replicate and cause a productive infection. The assay also benefits from detecting VNA alone, in contrast to ELISA, but similar to FAVN, gives a more accurate picture of the protective antibodies present in the sample. Over 60 sera from various host species were evaluated for neutralizing antibodies against the CVS-11 G-protein. The results show that the pseudotype assay is 100&#x0200a;&#x00025; specific and equally sensitive compared with the WHO&#x0002f;OIE-approved FAVN assay, as shown by effective differentiation between positive and negative sera and by accurately reflecting VNA titres for the positive sera.</p><p id="__p25">It has been reported that human sera from recipients of the RABV HDCV can cross-neutralize EBLV-1 and EBLV-2 &#x00028;<a href="#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512548">Brookes <em>et al.</em>, 2005</a>; <a href="#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512558">Hanlon <em>et al.</em>, 2005</a>&#x00029;. Confirmation of these observations using pseudotypes is consistent with the notion that G-protein is the target for neutralizing antibody because it is the only lyssavirus protein present in the pseudotype particle. Furthermore, our results show that antibodies in serum from vaccinated animals, specifically targeting the G-protein, cross-neutralize distinct lyssavirus genotypes to varying titres depending on viral genotype and the animal that the serum was obtained from. G-protein antibody responses in humans and cats were higher against CVS-11 infections, followed by EBLV-2 and finally EBLV-1, but additional samples need testing to confirm this observation. This result is to be expected to some extent, given that the samples were from RABV-vaccinated individuals. As expected, the rabbit serum, which was raised against EBLV-2, neutralized this genotype at higher dilutions than CVS-11 and EBLV-1.</p><p id="__p26">Our cross-neutralization data for CVS-11 versus EBLV-1 or EBLV-2 support the hypothesis that the higher the degree of similarity between G-protein sequences the more comparable the neutralization titres &#x00028;<a href="#r4" rid="r4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512561">Brookes <em>et al.</em>, 2005</a>; <a href="#r19" rid="r19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512534">Hanlon <em>et al.</em>, 2005</a>&#x00029;. The lower <em>r</em><sup>2</sup> value for EBLV-1 versus EBLV-2 does not support this hypothesis, however, as the EBLVs have a higher sequence identity to each other than to CVS-11. It is likely that this is due to all but one of the sera used in these experiments being raised only against RABV-based vaccines. In addition, the small sample size and individual variation may influence the results. This illustrates the difficulties in interpretation of antigenic differences using cross-neutralization data. A wider study using multiple representatives from each genotype, with sera raised against multiple genotypes, may assist in further quantifying antigenic differences between lyssaviruses.</p><p id="__p27">The cross-neutralization of lentiviral pseudotypes bearing lyssavirus envelopes will provide the opportunity to analyse neutralizing epitopes in G-proteins quantitatively and qualitatively. The method described here can be extended to other lyssaviruses in phylogroups 1 and 2. Because cDNA cloned into plasmids is used to generate the pseudotype, site-specific mutagenesis can be exploited to elucidate which domains are crucial for G-protein function in effecting virion attachment and entry, and which neutralizing epitopes determine strain-specific and group-specific responses to sera and to monoclonal antibodies.</p><p id="__p28">For the adoption of neutralization assays, using either replication-competent or pseudotype viruses, there are some issues that need to be addressed before the assay can be employed for routine serological surveillance. In both systems, there will be free or secreted envelope protein in the virus preparations that can adsorb antibody from the supernatant and thus skew neutralization tests. It is therefore important to standardize virus input in order to obtain the most sensitive and reliable results. This can be achieved by determining the concentration of virus at which a known negative serum becomes positive, and by using a concentration of virus slightly greater than that routinely used by rabies reference laboratories as part of their assay validation process. Alternatively, where a baseline positive control is available, for example the OIE reference standard for RABV neutralization assays, the smallest amount of virus that is needed to achieve an IC<sub>100</sub> at the lowest serum dilution could be determined. This will allow for the greatest range of serum dilutions to be tested, while all negative samples will provide a &#x02018;failed&#x02019; result. For our assay, this result was achieved using a virus input between 10&#x000d7;TCID<sub>50</sub> &#x00028;1&#x000d7;10<sup>5</sup> RLU&#x00029; and 100&#x000d7;TCID<sub>50</sub> &#x00028;1&#x000d7;10<sup>6</sup> RLU&#x00029;. Therefore, we would recommend 10&#x02013;100&#x000d7;TCID<sub>50</sub> or 1&#x000d7;10<sup>5</sup>&#x02013;1&#x000d7;10<sup>6</sup> RLU virus input for neutralization assays using the CVS-11 pseudotype. While background readings for cells alone or virus alone were 50&#x02013;200 RLU, luciferase carry-over for &#x00394;Env samples and those pseudotypes that produced a negative GFP result was up to 1&#x000d7;10<sup>4</sup> RLU, depending on the cell line used &#x00028;with 50&#x02005;&#x003bc;l pseudotype input&#x00029;. Therefore, the &#x00394;Env value should be considered the cut-off for a positive viral titre when using large volumes of pseudotype. However, as only 0.1&#x02013;0.5&#x02005;&#x003bc;l of pseudotype virus is normally used, the &#x02018;virus alone&#x02019; luciferase reading is generally larger than that which would be observed with &#x00394;Env and is therefore used as the background value.</p><p id="__p29">It was encouraging to observe that BHK cells, which are routinely used in live virus CVS-11 FAVN tests, were highly permissive for our CVS-11 pseudotype. Conversely, N2A cells that were readily infected by live lyssaviruses were not permissive for the CVS-11 pseudotype with HIV core. In contrast, MLV-based pseudotypes, made using different reporter constructs, were able to infect N2A cells, suggesting a post-entry restriction imposed selectively on the lentiviral reporter gene in the vector. This could be due to a specific restriction of the pCSGW and pCSFLW promoter in this cell line, because N2A cells were also almost completely refractory to infection by VSV, EBLV-1 and EBLV-2 pseudotypes produced with the same HIV reporter plasmids &#x00028;data not shown&#x00029;. Alternatively, the lentiviral core may be subject to a post-penetration restriction in N2A cells, such as TRIM5<em>&#x003b1;</em> &#x00028;<a href="#r32" rid="r32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512529">Towers, 2007</a>&#x00029;.</p><p id="__p30">The fatality rate of RABV infections in humans who have not received either pre- or post-exposure prophylaxis is very high, nearing 100&#x0200a;&#x00025;. Compared with the diseases caused by other highly pathogenic viruses, such as Ebola virus haemorrhagic fever &#x00028;80&#x0200a;&#x00025; fatality&#x00029; and H5N1 influenza &#x00028;61&#x0200a;&#x00025;&#x00029;, the ongoing research and surveillance for RABV is limited, supporting the suggestion that rabies is a &#x02018;neglected disease&#x02019;, especially in rabies-endemic countries in Africa and Asia &#x00028;<a href="#r34" rid="r34" class=" bibr popnode">WHO, 2006</a>; <a href="#r17" rid="r17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512553">Fooks, 2005</a>&#x00029;. There is, therefore, a need to readdress this balance by increasing the current level of surveillance for RABV in countries where the infection causes high levels of mortality. This would also help to limit misdiagnosis and consequent underreporting of RABV infection &#x00028;<a href="#r21" rid="r21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512546">Mallewa <em>et al.</em>, 2007</a>&#x00029;. The main assay currently being used &#x00028;FAVN&#x00029; provides good sensitivity and specificity, but requires handling of live RABV. Alternative assays for the detection of RABV antibodies, such as ELISA &#x00028;<a href="#r7" rid="r7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512531">Cliquet <em>et al.</em>, 2004</a>&#x00029; and rapid fluorescent focus inhibition test-GFP &#x00028;<a href="#r20" rid="r20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_159512549">Khawplod <em>et al.</em>, 2005</a>&#x00029;, have been designed; however, the former does not differentiate between neutralizing and non-neutralizing antibodies and the latter still requires high containment-level facilities.</p><p id="__p31" class="p p-last">The use of pseudotypes for the detection of VNAs removes the need to use live viruses and provides both high sensitivity and high specificity for the detection of neutralizing antibodies. Incorporation of GFP or luciferase as a reporter gene makes this assay applicable to many laboratories involved in RABV surveillance, and a good candidate for high throughput screening. For laboratories lacking fluorescence or luciferase detection, a <em>&#x003b2;</em>-galactosidase reporter could be used. It is also amenable to testing for the presence of antibodies in small volumes of sera &#x00028;microassay&#x00029; such as may be obtained from bats. In conclusion, this report shows that it is possible to analyse cross-neutralizing antibody responses against different lyssavirus genotypes using lentiviral pseudotypes. This approach could greatly improve the surveillance of new and emerging lyssaviruses and evaluation of the protection that current vaccines offer against these pathogens.</p></div><div id="__sec14" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="__sec14title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="PMC_1">\n            \n               <!--caption a9--><strong>[Supplementary Material]</strong>\n            \n            <div class="sup-box half_rhythm" id="idm139956935287312"><a href="/pmc/articles/PMC2886951/bin/supp_89_9_2204__index.html" data-ga-action="click_feat_suppl">Click here to view.</a></div>\n            \n         </div></div><div id="idm139957006432000" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139957006432000title">Acknowledgments</h2><div class="sec"><p id="__p32">These data were presented at the &#x02018;Rabies in the Americas&#x02019; &#x00028;RITA&#x00029; conference, held in Guanajuato, Mexico in October 2007. We thank Mrs Trudy Goddard for undertaking the FAVN assays and making available the serum samples and relevant data, Ms Karen Mansfield for providing CVS-11 RNA, Mr Daniel Horton and Dr Nicholas Johnson for assistance with Western blots and constructive discussions, and Mr Luciano Vozzolo for his guidance regarding the purification of pseudotype particles. This work was supported by the UK Medical Research Council &#x00028;grant numbers G8712499 and G0600369&#x00029; and the UK Department for Environment, Food and Rural Affairs &#x00028;Defra grant number SEV3800&#x00029;.</p></div></div><div id="idm139956935718336" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139956935718336title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139956935718208"><p id="__p33" class="p p-first-last">A supplementary figure and two supplementary tables are available with the online version of this paper.</p></p></div></div><div id="idm139956929036288" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139956929036288title">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:none"><li class="half_rhythm" id="r1"><span class="mixed-citation">Badrane, H., Bahloul, C., Perrin, P. &#x00026; Tordo, N. (2001). Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. <span class="ref-journal">J Virol</span> <span class="ref-vol">75</span>, 3268&#x02013;3276. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC114120/">PMC free article</a>]</span> [<a href="/pubmed/11238853" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;volume=75&amp;publication_year=2001&amp;pages=3268&amp;pmid=11238853&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r2"><span class="mixed-citation">Bartosch, B., Bukh, J., Meunier, J. C., Granier, C., Engle, R. E., Blackwelder, W. C., Emerson, S. U., Cosset, F. L. &#x00026; Purcell, R. H. (2003). <em>In vitro</em> assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. <span class="ref-journal">Proc Natl Acad Sci U S A</span> <span class="ref-vol">100</span>, 14199&#x02013;14204. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC283569/">PMC free article</a>]</span> [<a href="/pubmed/14617769" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;volume=100&amp;publication_year=2003&amp;pages=14199&amp;pmid=14617769&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r3"><span class="mixed-citation">Bresson, J. L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., Hoschler, K. &#x00026; Zambon, M. C. (2006). Safety and immunogenicity of an inactivated split-virion influenza A&#x0002f;Vietnam&#x0002f;1194&#x0002f;2004 &#x00028;H5N1&#x00029; vaccine: phase I randomised trial. <span class="ref-journal">Lancet</span> <span class="ref-vol">367</span>, 1657&#x02013;1664. [<a href="/pubmed/16714186" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;volume=367&amp;publication_year=2006&amp;pages=1657&amp;pmid=16714186&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r4"><span class="mixed-citation">Brookes, S. M., Parsons, G., Johnson, N., McElhinney, L. M. &#x00026; Fooks, A. R. (2005). Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. <span class="ref-journal">Vaccine</span> <span class="ref-vol">23</span>, 4101&#x02013;4109. [<a href="/pubmed/15964478" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;volume=23&amp;publication_year=2005&amp;pages=4101&amp;pmid=15964478&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r5"><span class="mixed-citation">Clapham, P., Nagy, K. &#x00026; Weiss, R. A. (1984). Pseudotypes of human T-cell leukemia virus types 1 and 2: neutralization by patients\' sera. <span class="ref-journal">Proc Natl Acad Sci U S A</span> <span class="ref-vol">81</span>, 2886&#x02013;2889. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC345177/">PMC free article</a>]</span> [<a href="/pubmed/6326149" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;volume=81&amp;publication_year=1984&amp;pages=2886&amp;pmid=6326149&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r6"><span class="mixed-citation">Cliquet, F., Aubert, M. &#x00026; Sagne, L. (1998). Development of a fluorescent antibody virus neutralisation test &#x00028;FAVN test&#x00029; for the quantitation of rabies-neutralising antibody. <span class="ref-journal">J Immunol Methods</span> <span class="ref-vol">212</span>, 79&#x02013;87. [<a href="/pubmed/9671155" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Immunol+Methods&amp;volume=212&amp;publication_year=1998&amp;pages=79&amp;pmid=9671155&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r7"><span class="mixed-citation">Cliquet, F., McElhinney, L. M., Servat, A., Boucher, J. M., Lowings, J. P., Goddard, T., Mansfield, K. L. &#x00026; Fooks, A. R. (2004). Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. <span class="ref-journal">J Virol Methods</span> <span class="ref-vol">117</span>, 1&#x02013;8. [<a href="/pubmed/15019254" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol+Methods&amp;volume=117&amp;publication_year=2004&amp;pages=1&amp;pmid=15019254&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r8"><span class="mixed-citation">Condit, R. C. (2001). Principles of Virology. In <em>Fields Virology</em>, 4th edn, vol. 1, pp. 19&#x02013;51. Edited by D. M. Knipe &#x00026; P. M. Howley. Philadelphia: Lippincott Williams &#x00026; Wilkins.</span></li><li class="half_rhythm" id="r9"><span class="mixed-citation">Cox, J. H., Dietzschold, B. &#x00026; Schneider, L. G. (1977). Rabies virus glycoprotein. II. Biological and serological characterization. <span class="ref-journal">Infect Immun</span> <span class="ref-vol">16</span>, 754&#x02013;759. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC421026/">PMC free article</a>]</span> [<a href="/pubmed/408269" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Infect+Immun&amp;volume=16&amp;publication_year=1977&amp;pages=754&amp;pmid=408269&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r10"><span class="mixed-citation">Cox, R. J., Mykkeltvedt, E., Robertson, J. &#x00026; Haaheim, L. R. (2002). Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. <span class="ref-journal">Scand J Immunol</span> <span class="ref-vol">55</span>, 14&#x02013;23. [<a href="/pubmed/11841688" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Scand+J+Immunol&amp;volume=55&amp;publication_year=2002&amp;pages=14&amp;pmid=11841688&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r11"><span class="mixed-citation">Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F. &#x00026; Weiss, R. A. (1984). The CD4 &#x00028;T4&#x00029; antigen is an essential component of the receptor for the AIDS retrovirus. <span class="ref-journal">Nature</span> <span class="ref-vol">312</span>, 763&#x02013;767. [<a href="/pubmed/6096719" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;volume=312&amp;publication_year=1984&amp;pages=763&amp;pmid=6096719&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r12"><span class="mixed-citation">Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M. &#x00026; Thrasher, A. J. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. <span class="ref-journal">Hum Gene Ther</span> <span class="ref-vol">13</span>, 803&#x02013;813. [<a href="/pubmed/11975847" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Gene+Ther&amp;volume=13&amp;publication_year=2002&amp;pages=803&amp;pmid=11975847&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r13"><span class="mixed-citation">Desmaris, N., Bosch, A., Salaun, C., Petit, C., Prevost, M. C., Tordo, N., Perrin, P., Schwartz, O., de Rocquigny, H. &#x00026; other authors (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. <span class="ref-journal">Mol Ther</span> <span class="ref-vol">4</span>, 149&#x02013;156. [<a href="/pubmed/11482987" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Ther&amp;volume=4&amp;publication_year=2001&amp;pages=149&amp;pmid=11482987&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r14"><span class="mixed-citation">Dietzschold, B., Lafon, M., Wang, H., Otvos, L., Jr, Celis, E., Wunner, W. H. &#x00026; Koprowski, H. (1987). Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteins. <span class="ref-journal">Virus Res</span> <span class="ref-vol">8</span>, 103&#x02013;125. [<a href="/pubmed/2445121" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virus+Res&amp;volume=8&amp;publication_year=1987&amp;pages=103&amp;pmid=2445121&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r15"><span class="mixed-citation">DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H. &#x00026; Calos, M. P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. <span class="ref-journal">Mol Cell Biol</span> <span class="ref-vol">7</span>, 379&#x02013;387. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC365079/">PMC free article</a>]</span> [<a href="/pubmed/3031469" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Biol&amp;volume=7&amp;publication_year=1987&amp;pages=379&amp;pmid=3031469&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r16"><span class="mixed-citation">Fooks, A. (2004). The challenge of new and emerging lyssaviruses. <span class="ref-journal">Expert Rev Vaccines</span> <span class="ref-vol">3</span>, 333&#x02013;336. [<a href="/pubmed/15270628" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Vaccines&amp;volume=3&amp;publication_year=2004&amp;pages=333&amp;pmid=15270628&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r17"><span class="mixed-citation">Fooks, A. R. (2005). Rabies remains a &#x02018;neglected disease&#x02019;. <span class="ref-journal">Euro Surveill</span> <span class="ref-vol">10</span>, 211&#x02013;212. [<a href="/pubmed/16972345" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Euro+Surveill&amp;volume=10&amp;publication_year=2005&amp;pages=211&amp;pmid=16972345&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r18"><span class="mixed-citation">Fooks, A. R., Brookes, S. M., Johnson, N., McElhinney, L. M. &#x00026; Hutson, A. M. (2003). European bat lyssaviruses: an emerging zoonosis. <span class="ref-journal">Epidemiol Infect</span> <span class="ref-vol">131</span>, 1029&#x02013;1039. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2870049/">PMC free article</a>]</span> [<a href="/pubmed/14959767" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epidemiol+Infect&amp;volume=131&amp;publication_year=2003&amp;pages=1029&amp;pmid=14959767&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r19"><span class="mixed-citation">Hanlon, C. A., Kuzmin, I. V., Blanton, J. D., Weldon, W. C., Manangan, J. S. &#x00026; Rupprecht, C. E. (2005). Efficacy of rabies biologics against new lyssaviruses from Eurasia. <span class="ref-journal">Virus Res</span> <span class="ref-vol">111</span>, 44&#x02013;54. [<a href="/pubmed/15896401" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virus+Res&amp;volume=111&amp;publication_year=2005&amp;pages=44&amp;pmid=15896401&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r20"><span class="mixed-citation">Khawplod, P., Inoue, K., Shoji, Y., Wilde, H., Ubol, S., Nishizono, A., Kurane, I. &#x00026; Morimoto, K. (2005). A novel rapid fluorescent focus inhibition test for rabies virus using a recombinant rabies virus visualizing a green fluorescent protein. <span class="ref-journal">J Virol Methods</span> <span class="ref-vol">125</span>, 35&#x02013;40. [<a href="/pubmed/15737414" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol+Methods&amp;volume=125&amp;publication_year=2005&amp;pages=35&amp;pmid=15737414&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r21"><span class="mixed-citation">Mallewa, M., Fooks, A. R., Banda, D., Chikungwa, P., Mankhambo, L., Molyneux, E., Molyneux, M. E. &#x00026; Solomon, T. (2007). Rabies encephalitis in malaria-endemic area, Malawi, Africa. <span class="ref-journal">Emerg Infect Dis</span> <span class="ref-vol">13</span>, 136&#x02013;139. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2725806/">PMC free article</a>]</span> [<a href="/pubmed/17370529" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;volume=13&amp;publication_year=2007&amp;pages=136&amp;pmid=17370529&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r22"><span class="mixed-citation">Mazarakis, N. D., Azzouz, M., Rohll, J. B., Ellard, F. M., Wilkes, F. J., Olsen, A. L., Carter, E. E., Barber, R. D., Baban, D. F. &#x00026; other authors (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. <span class="ref-journal">Hum Mol Genet</span> <span class="ref-vol">10</span>, 2109&#x02013;2121. [<a href="/pubmed/11590128" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mol+Genet&amp;volume=10&amp;publication_year=2001&amp;pages=2109&amp;pmid=11590128&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r23"><span class="mixed-citation">Mentis, G. Z., Gravell, M., Hamilton, R., Shneider, N. A., O\'Donovan, M. J. &#x00026; Schubert, M. (2006). Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. <span class="ref-journal">J Neurosci Methods</span> <span class="ref-vol">157</span>, 208&#x02013;217. [<a href="/pubmed/16725205" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Neurosci+Methods&amp;volume=157&amp;publication_year=2006&amp;pages=208&amp;pmid=16725205&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r24"><span class="mixed-citation">Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. &#x00026; Trono, D. (1996). <em>In vivo</em> gene delivery and stable transduction of nondividing cells by a lentiviral vector. <span class="ref-journal">Science</span> <span class="ref-vol">272</span>, 263&#x02013;267. [<a href="/pubmed/8602510" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;volume=272&amp;publication_year=1996&amp;pages=263&amp;pmid=8602510&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r25"><span class="mixed-citation">Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F. L. &#x00026; Dubuisson, J. (2004). Characterization of functional hepatitis C virus envelope glycoproteins. <span class="ref-journal">J Virol</span> <span class="ref-vol">78</span>, 2994&#x02013;3002. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC353750/">PMC free article</a>]</span> [<a href="/pubmed/14990718" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;volume=78&amp;publication_year=2004&amp;pages=2994&amp;pmid=14990718&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r26"><span class="mixed-citation">Soda, Y., Shimizu, N., Jinno, A., Liu, H. Y., Kanbe, K., Kitamura, T. &#x00026; Hoshino, H. (1999). Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. <span class="ref-journal">Biochem Biophys Res Commun</span> <span class="ref-vol">258</span>, 313&#x02013;321. [<a href="/pubmed/10329384" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;volume=258&amp;publication_year=1999&amp;pages=313&amp;pmid=10329384&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r27"><span class="mixed-citation">Stoker, M. &#x00026; Macpherson, I. (1964). Syrian hamster fibroblast cell line BHK21 and its derivatives. <span class="ref-journal">Nature</span> <span class="ref-vol">203</span>, 1355&#x02013;1357. [<a href="/pubmed/14207308" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;volume=203&amp;publication_year=1964&amp;pages=1355&amp;pmid=14207308&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r28"><span class="mixed-citation">Stratton, M. R., Darling, J., Pilkington, G. J., Lantos, P. L., Reeves, B. R. &#x00026; Cooper, C. S. (1989). Characterization of the human cell line TE671. <span class="ref-journal">Carcinogenesis</span> <span class="ref-vol">10</span>, 899&#x02013;905. [<a href="/pubmed/2650908" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Carcinogenesis&amp;volume=10&amp;publication_year=1989&amp;pages=899&amp;pmid=2650908&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r29"><span class="mixed-citation">Takeuchi, Y., Porter, C. D., Strahan, K. M., Preece, A. F., Gustafsson, K., Cosset, F. L., Weiss, R. A. &#x00026; Collins, M. K. (1996). Sensitization of cells and retroviruses to human serum by &#x00028;alpha 1&#x02013;3&#x00029; galactosyltransferase. <span class="ref-journal">Nature</span> <span class="ref-vol">379</span>, 85&#x02013;88. [<a href="/pubmed/8538747" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;volume=379&amp;publication_year=1996&amp;pages=85&amp;pmid=8538747&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r30"><span class="mixed-citation">Temperton, N. J., Chan, P. K., Simmons, G., Zambon, M. C., Tedder, R. S., Takeuchi, Y. &#x00026; Weiss, R. A. (2005). Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. <span class="ref-journal">Emerg Infect Dis</span> <span class="ref-vol">11</span>, 411&#x02013;416. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3298259/">PMC free article</a>]</span> [<a href="/pubmed/15757556" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;volume=11&amp;publication_year=2005&amp;pages=411&amp;pmid=15757556&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r31"><span class="mixed-citation">Temperton, N. J., Hoschler, K., Major, D., Nicolson, C., Manvell, R., Hien, V. M., Ha, D. Q., Jong, M. D., Zambon, M. &#x00026; other authors (2007). A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. <span class="ref-journal">Influenza Resp Viruses</span> <span class="ref-vol">1</span>, 105&#x02013;112. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4941878/">PMC free article</a>]</span> [<a href="/pubmed/19453415" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Influenza+Resp+Viruses&amp;volume=1&amp;publication_year=2007&amp;pages=105&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r32"><span class="mixed-citation">Towers, G. J. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. <span class="ref-journal">Retrovirology</span> <span class="ref-vol">4</span>, 40. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1906832/">PMC free article</a>]</span> [<a href="/pubmed/17565686" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Retrovirology&amp;volume=4&amp;publication_year=2007&amp;pages=40&amp;pmid=17565686&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r33"><span class="mixed-citation">Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P. &#x00026; Danos, O. (2000). A conserved mechanism of retrovirus restriction in mammals. <span class="ref-journal">Proc Natl Acad Sci U S A</span> <span class="ref-vol">97</span>, 12295&#x02013;12299. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC17335/">PMC free article</a>]</span> [<a href="/pubmed/11027299" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;volume=97&amp;publication_year=2000&amp;pages=12295&amp;pmid=11027299&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r34"><span class="mixed-citation">WHO (2006). <em>Rabies</em>. Fact Sheet No. 99. Geneva, World Helath Organisation.</span></li><li class="half_rhythm" id="r35"><span class="mixed-citation">Wool-Lewis, R. J. &#x00026; Bates, P. (1998). Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. <span class="ref-journal">J Virol</span> <span class="ref-vol">72</span>, 3155&#x02013;3160. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC109772/">PMC free article</a>]</span> [<a href="/pubmed/9525641" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;volume=72&amp;publication_year=1998&amp;pages=3155&amp;pmid=9525641&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li class="half_rhythm" id="r36"><span class="mixed-citation">Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. &#x00026; Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. <span class="ref-journal">Nat Biotechnol</span> <span class="ref-vol">15</span>, 871&#x02013;875. [<a href="/pubmed/9306402" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Biotechnol&amp;volume=15&amp;publication_year=1997&amp;pages=871&amp;pmid=9306402&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2886951&amp;issue-id=188230&amp;journal-id=1255&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">The Journal of General Virology</span> are provided here courtesy of <strong>Microbiology Society</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2886951/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2886951/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2886951/pdf/2204.pdf">PDF (526K)</a></li> | <li><a href="#" data-citationid="PMC2886951" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2886951%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2886951%2F&amp;text=Investigating%20antibody%20neutralization%20of%20lyssaviruses%20using%20lentiviral%20pseudotypes%3A%20a%20cross-species%20comparison"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2886951%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="18753230" data-aiid="2886951" data-aid="2886951" data-iid="188230" data-domainid="1255" data-domain="vir" data-accid="PMC2886951" data-md5="cc462bee85d2be3fd2ec8aea01e22a6d"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:41:25-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B35F5E9A34A6100000000098F098D&amp;ncbi_session=8A1B35F5E9A4CB41_2447SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2886951%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=vir&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2886951/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B35F5E9A4CB41_2447SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'